Navigation Links
Third generation Small pox vaccine from Cell-culture

Richard Greenberg and colleagues compared their Cell culture small pox vaccine// (CCSV) derived from cell culture with calf lymph derived vaccine. Small pox vaccine currently used is a live, attenuated vaccine virus derived from calf lymph. This vaccine produces adverse effects in vaccinated, 15-42 develop serious or life threatening adverse reactions of every million. 1 to 2 people every million die because of this vaccine. Serious side include eczema vaccinatum, progressive vaccinia, post vaccinal encephalitis, fetal vaccine, vaccina keratitis, myopericarditis.

Small pox vaccine is contraindicated in up to 30% or more population, including infants, pregnant women, immunocompromised, eczema patients, and cardiovascular conditions.

In this trial, the safety and immunogenecity, adverse effects were determined by neutralization, Antibody titers, T-cell proliferative response assays and interferon-? elispot. Only one vaccinated person developed pock lesions. The number of participants who became immune to the virus was high, with increased measures of cell mediated immunity in CCSV recipients. These results show CCSV vaccine is equally immunogenic and safe compared to calf lymph derived vaccine.

This new vaccine can solve the problem of calf lymph vaccine, as these existing stocks of calf lymph vaccine are mot than 20 years old, contamination by bovine prions can be avoided, unwanted immune response to bovine and other non-vaccina entities in vaccine.

Though, CCSV has advantages, we should be able to provide universal pre-exposure immunity to small pox. A safe, immunogenic, effective vaccine will provide a barrier against attempts to use small pox as a biological weapon. Research leading to the third generation vaccines, such as vaccinia viruses that are further attenuated, inactivated viruses, subunit or peptide based vaccines should have significant use to public health.


'"/>




Page: 1

Related medicine news :

1. Third artificial heart patient introduced
2. Surgery Offers Better Treatment For Third Degree Piles
3. One Third Of All Cancers Preventable!
4. Britain Announces Third Transfusion Related Mad Cow Case
5. Kleins Third Way Has Tough Opposition
6. Ignorance about AIDS rampart in Third of College Students: Chinese survey
7. Jalgaon: Third Phase Of Culling Operations Begin
8. Pramod Mahajan Undergoes Third Surgery
9. Third Arm Removed Successfully
10. Erection Drug Was Not Useful to Two-Thirds of Its Users
11. Babies Could Be exposed to Third Hand Smoke If Parents Are Smokers
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/12/2016)... Antonio, TX (PRWEB) , ... February 12, 2016 , ... ... love, as expressed in Blue SKies Buddha, the biography of Rama - Dr. Frederick ... fact a love story, the love of a Buddhist teacher for teaching and helping ...
(Date:2/12/2016)... ... February 12, 2016 , ... The Lymphoma Research ... lymphoma research and serving the lymphoma community through a comprehensive series of education ... Florida’s philanthropic community at its 10th anniversary Fashion Luncheon on Monday, February 8, ...
(Date:2/12/2016)... Middletown, PA (PRWEB) , ... February 12, 2016 , ... ... year’s event will be held in Anaheim, CA at the Anaheim Convention Center. Almost ... they can see new therapy products in action, learn more about their chosen field ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... ... firm announced that nominations have closed for the ISE Southeast Awards 2016. Finalists ... be announced at the ISE® Southeast Executive Forum and Awards Gala on March ...
(Date:2/12/2016)... ... 12, 2016 , ... Every winter, someone is killed, injured or loses a ... Burn Center, part of the Allegheny Health Network, has partnered with Etna Volunteer ... Heaters Need Space” campaign. , “Space Heaters Need Space” aims to bring ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... 12, 2016  Apellis Pharmaceuticals, Inc., today ... million Series D preferred stock financing, co-led ... Capital Group and venBio Global Strategic Fund, ... IB Investment, and Epidarex Capital. The proceeds of ... advance clinical trials in the Company,s ongoing ...
(Date:2/12/2016)... February 12, 2016 ... titled Chronic Inflammation Global Clinical Trials Review, H2, ... the global clinical trials landscape along with top ... Region, Country (G7 & E7), Trial Status, Trial ... reviews top companies involved and enlists all trials ...
(Date:2/11/2016)... , Feb. 11, 2016 The primary ... and future adoption patterns on the usage of liquid ... the following: - Timeframe of liquid biopsy ... ctDNA, cfDNA and Evs—by organization type - Sample inflow ... types: blood, saliva, stool, serum, and so on. - ...
Breaking Medicine Technology: